IMPACCT Real-World Evidence Summit 2026

Attendees, exhibitors & solutions

Who this event is for

Industry trends

Key trends shaping this market and its wider industry.

Arrival airports

Choose from the following airports, with convenient access to the event and venue.

Hotel tiers

A range of accommodation options near the venue and across key areas.

Local transport

Get around the city with these convenient transport options.

Frequently asked

Glossary

1

Real-World Data (RWD)

Health data collected outside controlled trials, including EHRs, claims, registries, patient-reported outcomes and wearable or home-monitoring data. At this event, RWD is discussed as an input whose provenance, completeness and fitness for a specific regulatory or payer question must be defended.

2

Real-World Evidence (RWE)

Clinical evidence about the use, benefits or risks of a medical product derived from RWD. Conference sessions examine when RWE can support label expansion, post-authorisation commitments, payer dossiers and comparative effectiveness claims.

3

HEOR

Health economics and outcomes research, the discipline that links clinical evidence to cost, quality of life and budget impact. Boston pharma and payer audiences use HEOR models to test whether an evidence package answers reimbursement questions.

4

Target trial emulation

A causal-inference method that designs an observational analysis to mimic the eligibility, treatment strategies, follow-up and outcomes of a hypothetical randomised trial. It appears in RWE methods sessions because it forces explicit assumptions about confounding and time zero.

5

Fit-for-purpose RWD

A dataset judged against the specific decision it must support, rather than against a single universal quality bar. At this conference, fit-for-purpose assessment covers data source validation, missingness, coding and linkage accuracy for regulatory or payer use.

6

Patient-Reported Outcomes (PROs)

Outcome measures reported directly by patients, often through validated instruments. PROs are discussed alongside registry and EHR data because they can capture symptoms, function and quality of life that claims data miss.

7

Data linkage

The process of connecting records across claims, EHR, registry or patient-generated sources using identifiers or probabilistic matching. Sessions on linkage focus on de-identification, consent, error propagation and whether the linked dataset remains fit for regulatory or HEOR use.

8

Payer value dossier

A evidence package prepared for health technology assessment or payer review, typically combining clinical, economic and patient-outcome evidence. At this event, teams compare how RWE and HEOR inputs are positioned in U.S. and global dossiers.

9

Regulatory-grade evidence

Evidence produced with documentation, traceability and pre-specified methods strong enough for regulatory review. Conference case studies examine protocols, data quality and audit trails needed when RWE is submitted rather than used only for internal decisions.

10

Decentralized clinical trial (DCT)

A trial model that uses remote visits, eConsent, direct-to-patient shipping or home-based data collection. DCT discussions connect to RWE because both rely on patient-generated and routinely collected data outside traditional site visits.

11

Claims data

Billing and utilisation records from insurers or health systems that show diagnoses, procedures, prescriptions and costs. At this conference, claims data is presented as a large but messy RWD source that needs careful coding and confounder control.

12

Registry data

Structured data collected for a defined patient population, often by disease or treatment. Registry sessions at this Boston event focus on recruitment, follow-up completeness and how registry evidence combines with claims or EHR data.